If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Biotechs Bolstered on 21st Century Cures Passage

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield